Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Stock analysts at Wedbush decreased their FY2016 EPS estimates for Sarepta Therapeutics in a research report issued to clients and investors on Monday. Wedbush analyst H. Behanna now anticipates that the firm will earn ($5.31) per share for the year, down from their previous forecast of ($5.24). Wedbush has a “Outperform” rating and a $72.00 price target on the stock. Wedbush also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($1.25) EPS, Q1 2017 earnings at ($1.15) EPS, Q2 2017 earnings at ($1.02) EPS, Q3 2017 earnings at ($0.99) EPS, Q4 2017 earnings at ($0.97) EPS, FY2017 earnings at ($4.14) EPS, FY2018 earnings at ($2.59) EPS and FY2019 earnings at ($0.93) EPS.
SRPT has been the topic of several other reports. JMP Securities upgraded Sarepta Therapeutics to an “outperform” rating and upped their target price for the company from $10.00 to $60.00 in a report on Monday, September 19th. Royal Bank Of Canada upgraded Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating and set a $83.00 target price on the stock in a report on Monday, September 19th. Cowen and Company reiterated an “outperform” rating and issued a $64.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, October 5th. Leerink Swann reiterated an “underperform” rating and issued a $5.00 target price on shares of Sarepta Therapeutics in a report on Thursday, August 4th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $102.00 target price on shares of Sarepta Therapeutics in a report on Friday, September 30th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $58.44.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 54.19 on Wednesday. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $63.73. The stock has a 50 day moving average of $44.27 and a 200-day moving average of $26.36. The firm’s market capitalization is $2.60 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the business posted ($0.87) EPS.
Several large investors have recently made changes to their positions in SRPT. Teacher Retirement System of Texas raised its stake in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares in the last quarter. Advisor Group Inc. purchased a new position in Sarepta Therapeutics during the second quarter valued at $154,000. Quantitative Systematic Strategies LLC purchased a new position in Sarepta Therapeutics during the second quarter valued at $211,000. BNP Paribas Arbitrage SA increased its position in Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock valued at $217,000 after buying an additional 1,886 shares during the last quarter. Finally, National Planning Corp increased its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the last quarter. 65.29% of the stock is owned by hedge funds and other institutional investors.
In other news, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the sale, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP David T. Howton sold 9,304 shares of the firm’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $465,200.00. Following the sale, the senior vice president now directly owns 11,168 shares of the company’s stock, valued at $558,400. The disclosure for this sale can be found here. Insiders own 10.90% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.